Cargando…

Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate

Traditional eye drops used for topically administering drugs have poor ocular bioavailability due to the biological barriers of the eye. There is an interest to design and develop novel drug delivery systems that would extend the precorneal residence time, reduce the frequency of administration and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalaria, Vishwa J., Saisivam, S., Alshishani, Anas, Aljariri Alhesan, Jameel S., Chakraborty, Sumit, Rahamathulla, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191058/
https://www.ncbi.nlm.nih.gov/pubmed/36876464
http://dx.doi.org/10.1080/10717544.2023.2185180
_version_ 1785043395920527360
author Kalaria, Vishwa J.
Saisivam, S.
Alshishani, Anas
Aljariri Alhesan, Jameel S.
Chakraborty, Sumit
Rahamathulla, Mohamed
author_facet Kalaria, Vishwa J.
Saisivam, S.
Alshishani, Anas
Aljariri Alhesan, Jameel S.
Chakraborty, Sumit
Rahamathulla, Mohamed
author_sort Kalaria, Vishwa J.
collection PubMed
description Traditional eye drops used for topically administering drugs have poor ocular bioavailability due to the biological barriers of the eye. There is an interest to design and develop novel drug delivery systems that would extend the precorneal residence time, reduce the frequency of administration and decrease dose-related toxicity. This study aimed to prepare Nanoparticles of Gemifloxacin Mesylate and incorporate them into an in situ gel. The nanoparticles were prepared by ionic gelation technique, using 3(2) factorial design. Sodium tripolyphosphate (STPP) was used to crosslink Chitosan. The optimized formulation of the nanoparticles (GF4) contained 0.15% Gemifloxacin Mesylate, 0.15% Chitosan and 0.20% STPP, producing 71 nm particle size and 81.11% entrapment efficiency. The prepared nanoparticles showed biphasic release, with an initial burst release of 15% in 1.0 hr and a cumulative drug release of 90.53% at the end of 24 hrs. After that, the prepared nanoparticles were incorporated into an in situ gel, using Poloxamer 407, producing a sustained drug release with efficient antimicrobial activity against gram-positive and gram-negative bacteria as confirmed by the cup plate method.
format Online
Article
Text
id pubmed-10191058
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-101910582023-05-18 Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate Kalaria, Vishwa J. Saisivam, S. Alshishani, Anas Aljariri Alhesan, Jameel S. Chakraborty, Sumit Rahamathulla, Mohamed Drug Deliv Research Article Traditional eye drops used for topically administering drugs have poor ocular bioavailability due to the biological barriers of the eye. There is an interest to design and develop novel drug delivery systems that would extend the precorneal residence time, reduce the frequency of administration and decrease dose-related toxicity. This study aimed to prepare Nanoparticles of Gemifloxacin Mesylate and incorporate them into an in situ gel. The nanoparticles were prepared by ionic gelation technique, using 3(2) factorial design. Sodium tripolyphosphate (STPP) was used to crosslink Chitosan. The optimized formulation of the nanoparticles (GF4) contained 0.15% Gemifloxacin Mesylate, 0.15% Chitosan and 0.20% STPP, producing 71 nm particle size and 81.11% entrapment efficiency. The prepared nanoparticles showed biphasic release, with an initial burst release of 15% in 1.0 hr and a cumulative drug release of 90.53% at the end of 24 hrs. After that, the prepared nanoparticles were incorporated into an in situ gel, using Poloxamer 407, producing a sustained drug release with efficient antimicrobial activity against gram-positive and gram-negative bacteria as confirmed by the cup plate method. Taylor & Francis 2023-03-06 /pmc/articles/PMC10191058/ /pubmed/36876464 http://dx.doi.org/10.1080/10717544.2023.2185180 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Research Article
Kalaria, Vishwa J.
Saisivam, S.
Alshishani, Anas
Aljariri Alhesan, Jameel S.
Chakraborty, Sumit
Rahamathulla, Mohamed
Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate
title Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate
title_full Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate
title_fullStr Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate
title_full_unstemmed Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate
title_short Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate
title_sort design and evaluation of in situ gel eye drops containing nanoparticles of gemifloxacin mesylate
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191058/
https://www.ncbi.nlm.nih.gov/pubmed/36876464
http://dx.doi.org/10.1080/10717544.2023.2185180
work_keys_str_mv AT kalariavishwaj designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate
AT saisivams designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate
AT alshishanianas designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate
AT aljaririalhesanjameels designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate
AT chakrabortysumit designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate
AT rahamathullamohamed designandevaluationofinsitugeleyedropscontainingnanoparticlesofgemifloxacinmesylate